A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

A Global, Multicenter, Open-label, Single Agent, Two-stage Phase 2 Study to Evaluate the Efficacy and Safety of AMG 102 in Subjects With Advanced Renal Cell Carcinoma

The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.

Study Overview

• Status: Completed
• Conditions: Advanced Renal Cell Carcinoma
• Intervention / Treatment: Drug: AMG 102 at 20 mg/kg; Drug: AMG 102 at 10 mg/kg

• Study Type: Interventional
• Enrollment (Actual): 61
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• documented histologically confirmed advanced or metastatic renal cell carcinoma with the primary tumor in place or following nephrectomy
• measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (CT or MRI) or ≥ 10 mm by spiral CT scan
• no more than 3 relapses (or prior systemic treatments)
• unable to receive or failed prior therapy with vascular endothelial growth factor (VEGF) binding agents or VEGF receptor tyrosine kinase inhibitors or other multi-kinase inhibitors
• tissue blocks or tissue sections from initial or upon diagnosis of advanced metastatic disease are available for submission to the central laboratory within approximately 4 weeks after enrollment or approval is granted by the sponsor (upon receipt of justification why the sample is not available)
• age ≥ 18 years
• ECOG performance status of 0-2
• hemoglobin concentration ≥ 9 g/dL
• absolute neutrophil count ≥ 1.5 x 10(9th)/L
• corrected serum calcium ≤ 10 mg/dL
• either serum creatinine < 2.0 x upper limit of normal OR creatinine clearance > 40 mL/min
• alanine aminotransferase ≤ 2.5 times upper limit of normal or < 5.0 x ULN if the subject has documented liver metastasis or primary hepatic neoplasm
• serum total bilirubin ≤ 2.5 times upper limit of normal
• before any study-specific procedure, the appropriate written informed consent must be obtained

Exclusion Criteria:

• active brain metastases; brain metastases allowed provided they have been treated with surgery and/or radiation therapy and show no evidence of progression on cerebral CT or MRI scan 2 months following surgery and/or radiation therapy
• concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months before enrollment) that could compromise participation in the study
• documented history of human immunodeficiency virus infection
• documented history of viral chronic hepatitis
• received biologic, small molecule, immunotherapy, chemotherapy, radiotherapy or other agents to treat renal cancer within 28 days before enrollment
• treated previously with c-Met or HGF targeted therapy

• concurrent or prior (within 7 days before enrollment) anticoagulation therapy, except:

  • Use of low-dose warfarin (< 2 mg/day) for prophylaxis against central venous catheter thrombosis or
  • Use of low molecular weight heparins (LMWH, e.g., enoxaparin sodium [Lovenox] and unfractionated heparin for prophylaxis against central venous catheter thrombosis is allowed
• concurrent use of hormones or other chemotherapeutic agents except for steroids given for adrenal failure and hormones administered for non-disease-related conditions (eg, insulin for diabetes); except for non-cancer reasons
• concurrent palliative or therapeutic radiation therapy
• currently enrolled in or has not yet completed at least 30 days since ending other investigational device or therapy, or subject is receiving other investigational agent(s)
• active infection requiring treatment within 1 week before enrollment
• undergone major surgery within 4 weeks before enrollment or recovering from prior surgery
• past or current history of another neoplasm, except for curatively treated non-melanoma skin cancer, carcinoma in situ of the cervix and other primary solid cancer with no known active disease present and no curative treatment administered for the last 3 years
• known allergy or sensitivity to any of the excipients in the investigational product to be administered
• pregnant or is breast feeding

• not consenting to use adequate contraceptive precautions during the course of the study and for 6 months after the last administration of investigational product:

  • female subjects who are not post-menopausal (no menstrual period for a minimum of 12 months at study entry) or documented surgically sterile will not be bound to this exclusion
• previously treated with AMG 102
• previously enrolled into this study
• will not be available for follow-up assessments
• has other disorders that compromises the ability of the subject to give written informed consent and/or comply with study procedures
• unable to begin protocol specified treatment within 3 days after enrollment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: AMG 102 at 20 mg/kg Dose Level; Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed.	Drug: AMG 102 at 20 mg/kg; AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
EXPERIMENTAL: AMG 102 at 10 mg/kg Dose Level; Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed.	Drug: AMG 102 at 10 mg/kg; AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To assess the objective response rate in subjects with advanced renal cell carcinoma receiving AMG 102 treatment	9 weeks from first dose of AMG 102

Secondary Outcome Measures

Outcome Measure	Time Frame
To estimate the overall survival and progression free survival rates in this population	8 week intervals
To assess the duration of response and time to response in this population	treatment period
To assess the pharmacokinetics of AMG 102 in subjects with advanced renal cell carcinoma	Weeks 1, 5, and 9
To assess the safety profile of AMG 102 in subjects with advanced renal cell carcinoma	entire study

Collaborators and Investigators

• Sponsor: Amgen

Publications and helpful links

General Publications

• Schoffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. 2011 Sep;108(5):679-86. doi: 10.1111/j.1464-410X.2010.09947.x. Epub 2010 Dec 13.

Helpful Links

• AmgenTrials clinical trials website

Study record dates

Study Major Dates

• Study Start: January 1, 2007
• Primary Completion (ACTUAL): March 1, 2009
• Study Completion (ACTUAL): March 1, 2009

Study Registration Dates

• First Submitted: January 11, 2007
• First Submitted That Met QC Criteria: January 11, 2007
• First Posted (ESTIMATE): January 15, 2007

Study Record Updates

• Last Update Posted (ESTIMATE): April 10, 2015
• Last Update Submitted That Met QC Criteria: March 23, 2015
• Last Verified: March 1, 2015

More Information

Terms related to this study

• Keywords: Kidney Cancer; Renal Cancer
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Kidney Neoplasms; Carcinoma, Renal Cell; Carcinoma; Physiological Effects of Drugs; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Antibodies, Monoclonal; Rilotumumab
• Other Study ID Numbers: 20060100